{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:33:19Z","timestamp":1790357599122,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hellenic Journal of Cardiology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.hjc.2022.11.002","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T11:39:10Z","timestamp":1668685150000},"page":"65-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Current and emerging perspectives on pathophysiology, diagnosis, and management of hypertrophic cardiomyopathy"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2891-1469","authenticated-orcid":false,"given":"Ilias K.","family":"Gartzonikas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9900-9659","authenticated-orcid":false,"given":"Katerina K.","family":"Naka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aris","family":"Anastasakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"39","key":"10.1016\/j.hjc.2022.11.002_bib1","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.hjc.2022.11.002_bib2","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.hjc.2022.11.002_bib3","first-page":"e558","article-title":"2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.hjc.2022.11.002_bib4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hjc.2022.11.002_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjmed.2003.05.009","article-title":"Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults","volume":"116","author":"Zou","year":"2004","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.hjc.2022.11.002_bib6","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.amjcard.2004.03.007","article-title":"Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study)","volume":"93","author":"Maron","year":"2004","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.hjc.2022.11.002_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jacc.2012.02.068","article-title":"Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives","volume":"60","author":"Maron","year":"2012","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"10.1016\/j.hjc.2022.11.002_bib8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/cvr\/cvv025","article-title":"Genetic advances in sarcomeric cardiomyopathies: state of the art","volume":"105","author":"Ho","year":"2015","journal-title":"Cardiovasc Res"},{"issue":"24","key":"10.1016\/j.hjc.2022.11.002_bib9","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.jacc.2014.09.059","article-title":"Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations","volume":"64","author":"Coppini","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hjc.2022.11.002_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.hfc.2021.01.003","article-title":"Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy","volume":"17","author":"Limongelli","year":"2021","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.hjc.2022.11.002_bib11","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/eurheartj\/ehp216","article-title":"Myocardial bridging and sudden death in hypertrophic cardiomyopathy: Salome drops another veil","volume":"30","author":"Olivotto","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hjc.2022.11.002_bib12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00424-019-02259-2","article-title":"Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations","volume":"471","author":"Spudich","year":"2019","journal-title":"Arch Eur J Physiol"},{"issue":"4","key":"10.1016\/j.hjc.2022.11.002_bib13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/cvr\/cvv023","article-title":"Targets for therapy in sarcomeric cardiomyopathies","volume":"105","author":"Tardiff","year":"2015","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.hjc.2022.11.002_bib14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0168-9525(03)00081-7","article-title":"Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion","volume":"19","author":"Ashrafian","year":"2003","journal-title":"Trends Genet"},{"issue":"5","key":"10.1016\/j.hjc.2022.11.002_bib15","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.yjmcc.2010.06.006","article-title":"Normal passive viscoelasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathy","volume":"49","author":"Hoskins","year":"2010","journal-title":"J Mol Cell Cardiol"},{"issue":"5","key":"10.1016\/j.hjc.2022.11.002_bib16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","article-title":"Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy","volume":"127","author":"Coppini","year":"2013","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.hjc.2022.11.002_bib17","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1111\/bph.14223","article-title":"Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium","volume":"175","author":"Ferrantini","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.hjc.2022.11.002_bib18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s003950050134","article-title":"Altered force-frequency relation in hypertrophic obstructive cardiomyopathy","volume":"94","author":"Schotten","year":"1999","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.hjc.2022.11.002_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.003132","article-title":"Left ventricular outflow tract obstruc- tion in hypertrophic cardiomyopathy patients without severe septal hy- pertrophy: implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography","volume":"8","author":"Patel","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.hjc.2022.11.002_bib20","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1161\/CIRCULATIONAHA.114.013830","article-title":"Excess anterior mitral leaflet in a patient with hypertrophic obstructive cardiomyopathy and systolic anterior mo- tion","volume":"131","author":"Numata","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.hjc.2022.11.002_bib21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hjc.2022.11.002_bib22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.echo.2018.10.011","article-title":"Accuracy of jet direction on Doppler echocardiography in identifying the etiology of mitral regurgitation in obstructive hypertrophic cardiomyopathy","volume":"32","author":"Hang","year":"2019","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.hjc.2022.11.002_bib23","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jcmg.2018.02.002","article-title":"Myocardial stiffness evaluation using noninvasive shear wave imaging in healthy and hypertrophic cardiomyopathic adults","volume":"12","author":"Villemain","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.hjc.2022.11.002_bib24","first-page":"364","article-title":"Hypertrophic cardiomyopathy patients with paroxysmal atrial fibrillation have a high burden of left atrial fibrosis by cardiac magnetic resonance imaging","volume":"5","author":"Sivalokanathan","year":"2019","journal-title":"J\u00a0Am Coll Car- diol EP"},{"key":"10.1016\/j.hjc.2022.11.002_bib25","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/ehjci\/jex215","article-title":"Marked respiratory-related fluctuations in left ventricular outflow tract gradients in hypertrophic obstructive cardiomyopathy: An observational study","volume":"19","author":"Jain","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.hjc.2022.11.002_bib26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/01.CIR.71.2.234","article-title":"Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate va- sodilator reserve and elevated left ventricular filling pressures","volume":"71","author":"Cannon","year":"1985","journal-title":"Circulation"},{"key":"10.1016\/j.hjc.2022.11.002_bib27","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jacc.2012.12.024","article-title":"Blunted myocardial oxygenation response during vasodilator stress in patients with hypertrophic cardiomy- opathy","volume":"61","author":"Karamitsos","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hjc.2022.11.002_bib28","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1161\/01.CIR.0000097110.55312.BF","article-title":"Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease","volume":"108","author":"Sorajja","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.hjc.2022.11.002_bib29","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2016.11.063","article-title":"Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and man- agement","volume":"69","author":"Rowin","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hjc.2022.11.002_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13958-0","article-title":"Cardiovascular consequences of myocardial bridging: a meta-analysis and meta-regression","volume":"7","author":"Hostiuc","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.hjc.2022.11.002_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000486276","article-title":"Clinical outcomes of myocardial bridging versus no myocardial bridging in patients with apical hypertrophic cardio- myopathy","volume":"139","author":"Zhai","year":"2018","journal-title":"Cardiology"},{"key":"10.1016\/j.hjc.2022.11.002_bib32","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.amjcard.2013.11.062","article-title":"Heart rate recovery in patients with hypertrophic cardiomyopathy","volume":"113","author":"Patel","year":"2014","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.hjc.2022.11.002_bib33","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1249\/00005768-199311000-00006","article-title":"The effects of anabolic steroids on myocardial structure and cardiovascular fitness","volume":"25","author":"Sachtleben","year":"1993","journal-title":"Med Sci Sports Exerc"},{"issue":"1","key":"10.1016\/j.hjc.2022.11.002_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1399-3046.2005.00260.x","article-title":"Reversal of tacrolimus-related hypertrophic obstructive cardiomyopathy 5 years after kidney transplant in a 6-year-old recipient","volume":"9","author":"Jarzembowski","year":"2005","journal-title":"Pediatr Transplant"},{"issue":"14","key":"10.1016\/j.hjc.2022.11.002_bib35","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/0961203312462757","article-title":"Evidence for risk of cardiomyopathy with hydroxychloroquine","volume":"21","author":"Sumpter","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.hjc.2022.11.002_bib36","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/eurheartj\/ehs397","article-title":"Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.hjc.2022.11.002_bib37","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/eurheartj\/ehl041","article-title":"Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy","volume":"27","author":"Elliott","year":"2006","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.hjc.2022.11.002_bib38","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"issue":"32","key":"10.1016\/j.hjc.2022.11.002_bib39","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/eht070","article-title":"Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy","volume":"34","author":"Coats","year":"2013","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.hjc.2022.11.002_bib40","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCHEARTFAILURE.114.002248","article-title":"Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy","volume":"8","author":"Coats","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"6","key":"10.1016\/j.hjc.2022.11.002_bib41","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1161\/01.CIR.82.6.1995","article-title":"Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy","volume":"82","author":"Frenneaux","year":"1990","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.hjc.2022.11.002_bib42","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1161\/01.CIR.96.9.2987","article-title":"Prospective Prognostic Assessment of Blood Pressure Response During Exercise in Patients With Hypertrophic Cardiomyopathy","volume":"96","author":"Sadoul","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.hjc.2022.11.002_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/ejechocard\/jep157","article-title":"Echocardiography in hypertrophic cardiomyopathy diagnosis, prognosis, and role in management","volume":"10","author":"Williams","year":"2009","journal-title":"Eur J Echocardiogr"},{"issue":"6","key":"10.1016\/j.hjc.2022.11.002_bib44","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.hjc.2022.11.002_bib45","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2016.11.063","article-title":"Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management","volume":"69","author":"Rowin","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hjc.2022.11.002_bib46","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/hrt.2005.060962","article-title":"Distinguishing hypertrophic cardiomyopathy from athlete's heart: a clinical problem of increasing magnitude and significance","volume":"91","author":"Maron","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.hjc.2022.11.002_bib47","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jcu.22012","article-title":"Clinical value of carotid wave intensity analysis for differentiating nonobstructive hypertrophic cardiomyopathy from left ventricular hypertrophy secondary to systemic hypertension","volume":"41","author":"Li","year":"2013","journal-title":"J\u00a0Clin Ultrasound"},{"issue":"6","key":"10.1016\/j.hjc.2022.11.002_bib48","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.mayocp.2014.01.025","article-title":"Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy","volume":"89","author":"Bos","year":"2014","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.hjc.2022.11.002_bib49","first-page":"880","article-title":"Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity","volume":"17","author":"Alfares","year":"2015","journal-title":"Genet Med Off J Am Coll Med Genet"},{"issue":"2","key":"10.1016\/j.hjc.2022.11.002_bib50","article-title":"Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes","volume":"12","author":"Ingles","year":"2019","journal-title":"Circ Genomic Precis Med"},{"issue":"24","key":"10.1016\/j.hjc.2022.11.002_bib51","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1161\/01.CIR.0000042675.59901.14","article-title":"Prevalence and severity of \u201cbenign\u201d mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy","volume":"106","author":"Van Driest","year":"2002","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hjc.2022.11.002_bib52a","first-page":"625","article-title":"A\u00a0cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy","volume":"98","author":"Ingles","year":"2012","journal-title":"Heart Br Card Soc"},{"key":"10.1016\/j.hjc.2022.11.002_bib52b","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hjc.2022.11.002_bib53","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11886-020-01381-3","article-title":"Hypertrophic Cardiomyopathy 2020","volume":"22","author":"Kogut","year":"2020","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"10.1016\/j.hjc.2022.11.002_bib54","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1161\/CIRCULATIONAHA.109.878579","article-title":"Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy","volume":"121","author":"Maron","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.hjc.2022.11.002_bib55","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1253\/circj.CJ-10-0921","article-title":"Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy","volume":"74","author":"Maron","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.hjc.2022.11.002_bib56","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1161\/CIRCULATIONAHA.117.032838","article-title":"Association between race and clinical profile of patients referred for hypertrophic cardiomyopathy","volume":"137","author":"Wells","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.hjc.2022.11.002_bib57","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.amjcard.2012.04.051","article-title":"\u03b2 blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy","volume":"110","author":"Nistri","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hjc.2022.11.002_bib58","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hjc.2022.11.002_bib59","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy insights from the sarcomeric human cardiomyopathy registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.hjc.2022.11.002_bib60","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.amjcard.2012.04.030","article-title":"Cardiac transplantation in pa- tients with hypertrophic cardiomyopathy","volume":"110","author":"Kato","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hjc.2022.11.002_bib61","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/CIRCHEARTFAILURE.114.001843","article-title":"Clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy","volume":"8","author":"Pasqualucci","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.hjc.2022.11.002_bib62","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0735-1097(01)01727-2","article-title":"Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy","volume":"39","author":"Maron","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hjc.2022.11.002_bib63","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/europace\/euv339","article-title":"Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"18","author":"Zhao","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.hjc.2022.11.002_bib64","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.abb.2019.03.006","article-title":"Impaired calcium handling and mitochondrial metabolic dysfunction as early markers of hypertrophic cardiomyopathy","volume":"665","author":"Viola","year":"2019","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"10.1016\/j.hjc.2022.11.002_bib65","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11897-021-00523-0","article-title":"Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives","volume":"18","author":"Zampieri","year":"2021","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.hjc.2022.11.002_bib66","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.hjc.2022.11.002_bib67","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","article-title":"Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy","volume":"122","author":"Abozguia","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.hjc.2022.11.002_bib68","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamacardio.2018.4847","article-title":"Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial","volume":"4","author":"Coats","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hjc.2022.11.002_bib69","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","article-title":"Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study","volume":"11","author":"Olivotto","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hjc.2022.11.002_bib70","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002764","article-title":"Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) trial","volume":"9","author":"Olivotto","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"11","key":"10.1016\/j.hjc.2022.11.002_bib71","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.amjcard.2005.07.065","article-title":"Effect of losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy","volume":"96","author":"Araujo","year":"2005","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.hjc.2022.11.002_bib72","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.amjmed.2018.02.025","article-title":"Effect of spironolactone on myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy","volume":"131","author":"Maron","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.hjc.2022.11.002_bib73","doi-asserted-by":"crossref","first-page":"353","DOI":"10.21037\/acs.2017.07.07","article-title":"Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience","volume":"6","author":"Rastegar","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"issue":"11","key":"10.1016\/j.hjc.2022.11.002_bib74","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jacc.2015.06.1333","article-title":"Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction","volume":"66","author":"Maron","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hjc.2022.11.002_bib75","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2019.09.029","article-title":"Efficacy of combined Cox-Maze IV and ventricular septal myectomy for treatment of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy","volume":"125","author":"Boll","year":"2020","journal-title":"Am J Cardiol"},{"issue":"30","key":"10.1016\/j.hjc.2022.11.002_bib76","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1093\/eurheartj\/eht495","article-title":"Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population","volume":"35","author":"Veselka","year":"2014","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.hjc.2022.11.002_bib77","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jchf.2015.06.011","article-title":"A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy","volume":"3","author":"Liebregts","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hjc.2022.11.002_bib78","first-page":"2020","article-title":"ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease","volume":"29","author":"Pelliccia","year":"2020","journal-title":"Eur Heart J. Published online August"}],"container-title":["Hellenic Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1109966622001555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1109966622001555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:15:11Z","timestamp":1761099311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1109966622001555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":79,"alternative-id":["S1109966622001555"],"URL":"https:\/\/doi.org\/10.1016\/j.hjc.2022.11.002","relation":{},"ISSN":["1109-9666"],"issn-type":[{"value":"1109-9666","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and emerging perspectives on pathophysiology, diagnosis, and management of hypertrophic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Hellenic Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hjc.2022.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Hellenic Society of Cardiology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}